GLP1 agonist drugs, commonly known by brand names such as Ozempic and Mounjaro, reduce asthma symptoms in obese people ...

A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for the treatment of a chronic lung condition, the drugmaker said on Friday.

The new inhaler replaces Trixeo Aerosphere’s existing gas propellant with a low global warming-potential alternative.

European regulators have given their backing to a new eco-friendly inhaler that could help curb health care’s climate impact.